AT A GLANCE

11/07/2023

Coronavirus Disease 2019 (COVID-19),
Influenza, & Respiratory Syncytial Virus (RSV)

Updated weekly on Tuesdays, and current as of 3:00 p.m. on the date it was posted.

Note: As of October 17, 2023 this document will include updates for other respiratory diseases of public health concern, primarily influenza and respiratory syncytial virus (RSV).

Additionally, the “Guidelines and Technical documents” section [last updated July 26, 2023] will no longer be updated, but is archived as an appendix at the end of this document.

Moving forward, any news and guidance updates will be cycled through the New Content section below, as always with the dates of the latest additions bolded.

This document is a collation of resources for your reference. For official guidance on COVID-19, Influenza, and RSV in Ontario, please visit the Ministry of Health (COVID-19 | The Flu | RSV).

Table of Contents

New Content .................................................................................................................................. 3

Public Health Agencies.................................................................................................................................. 3

Public Health Agency of Canada | canada.ca ........................................................................................................ 3

BC Centre for Disease Control | bccdc.ca ........................................................................................................ 3

Institut national de santé publique | ........................................................................................................ 3

CDC: Centers for Disease Control and Prevention | cdc.gov .................................................................................. 3

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ........................................ 4

FDA: U.S. Food & Drug Administration | fda.gov .................................................................................. 5

UK Government | gov.uk ............................................................................................................................. 6

World Health Organization | who.int ................................................................................................................ 6

Other relevant government bodies / health care organizations .................................................................. 6

Center for Infectious Disease Research Policy | cidrap.umn.edu ................................................................ 7

National Collaborating Centre for Environmental Health | ncceh.ca .................................................................. 7

COVID-END | www.mcmasterforum.org/networks/covid-end ........................................................................ 7
Appendices.................................................................................................................. 8
Guidelines and Technical documents [ARCHIVED] .................................................. 8
Appendix I: General Guidelines [ARCHIVED] ......................................................... 8
  Ontario / Canada Main Page .................................................................................. 8
  Reopening/Rebuilding Guidelines ....................................................................... 8
  Vaccinations – General ....................................................................................... 9
  Vaccinations - Adverse Effects ........................................................................... 10
  Background Information/Case Definitions ........................................................ 11
  Laboratories ....................................................................................................... 11
  Miscellaneous Guidelines .................................................................................. 11
  Data & Surveillance .......................................................................................... 12
  Variants – Omicron ............................................................................................ 12
  Testing ................................................................................................................ 12
  Symptoms/Treatment ......................................................................................... 13
  COVID-19 Diagnosis in Children ..................................................................... 13
  Post-COVID-19 Condition .............................................................................. 14
  Case Investigation & Contact Tracing ............................................................... 14
  Infection Prevention and Control ..................................................................... 14
Appendix II: Guidelines for Health Sectors [ARCHIVED] .................................... 15
  Healthcare Providers ......................................................................................... 15
  Congregate Living (including Long-Term Care, Prisons, and Shelters) ............ 15
Appendix III: Guidelines for the Community [ARCHIVED] ............................. 16
  Travel, Transport & Borders .......................................................................... 16
  Schools / Childcare .......................................................................................... 16
  Mental Health/Substance Use Health .............................................................. 17
  Community/Workplaces .................................................................................. 17
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Beginning the week of December 6, 2021, Library Services switched from reporting daily to weekly COVID-19 trends. For daily case counts, you can check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- COVID-19 activity levels [updated 11-07-2023]
- Key COVID updates [updated 11-07-2023]
  - Weekly change in cases: 8,230
  - Total cases: 4,786,258
  - Weekly change in deaths: 140
  - Total deaths: 54,902
  - Weekly tests reported: 37,246
  - Weekly percent positivity: 17.9%
- Summary of National Advisory Committee on Immunization (NACI) statement of October 27, 2023 [10-27-2023]
- Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19 (PDF) [10-27-2023]
- COVID-19 daily epidemiology update [updated regularly]

BC Centre for Disease Control | bccdc.ca

- Respiratory epidemiological summary [11-02-2023]
- Respiratory surveillance
  - COVID-19 situation report [updated 11-02-2023]
  - Genomic surveillance [updated 11-02-2023]
  - Wastewater surveillance [updated 11-02-2023]
  - Acute care and long-term care outbreaks [updated 11-02-2023]
  - Emergency department visits for respiratory illness in BC [updated 11-03-2023]
  - Viral pathogen characterization [updated 11-02-2023]
  - Primary care visits for respiratory illness [updated 11-02-2023]
- COVID-19 vaccination toolkit for health professionals [updated 11-01-2023]

Institut national de santé publique | inspq.qc.ca

- Vigie de la COVID-19 dans les services de garde éducatifs à l’enfance - Octobre 2023 [10-13-2023]
- Portrait des situations d’éclosion de COVID-19 dans les milieux de travail du Québec de juin 2020 à décembre 2021 [10-10-2023]

CDC: Centers for Disease Control and Prevention | cdc.gov

- COVID-19 update for the United States [updated 11-06-2023]
- Weekly U.S. influenza surveillance report [updated 11-03-2023]
- Weekly viral respiratory illness snapshot [updated 11-03-2023]
The amount of respiratory illness causing people to seek healthcare is low in most areas of the country.

COVID-19 activity has not changed in many areas of the country and remains the cause of most new respiratory virus hospitalizations and deaths. Sustained increases in RSV activity regionally indicate the start of the 2023-2024 RSV season, with many parts of the country now experiencing elevated activity. Influenza activity remains low throughout much of the country, but small increases were reported in most areas. Hospital bed occupancy and capacity, including within intensive care units, remain stable nationally. Vaccines are available and can help protect people from the most serious health effects of fall and winter viruses.

- COVID-19 test positivity (percentage of tests conducted that were positive) has not changed nationally, and emergency department visits and hospitalizations remain stable. A group of Omicron variants (XBB and its sublineages) are the predominant lineages detected in the U.S., with HV.1 being most common. CDC is continuing to monitor HV.1, EG.5 and all other lineages.
- National test positivity, emergency department visits, and hospitalizations for influenza remain low.
- RSV activity is increasing in younger children. Emergency department visits for RSV continue to increase, primarily among younger children. Increases in RSV-associated hospitalizations among infants have been observed in most sites with RSV hospitalization monitoring.

- What to know about getting flu, COVID-19, and RSV vaccines at the same time [11-02-2023]
- 2023-2024 respiratory disease season outlook – October update [10-30-2023]
- Respiratory disease season outlook [updated 10-26-2023]
- Respiratory virus index [updated regularly]
- COVID Data Tracker [updated regularly]
- CDC respiratory virus updates [updated regularly]
- CDC Archive: Archived web material for CDC.gov is preserved on the CDC Archive Site. Note that the content on this site is for historical purposes only and is no longer being updated. The information here may be outdated and links may no longer function.

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- Prevention and control of infectious diseases among people who inject drugs - 2023 update [11-07-2023] [page 16]:
  Intervention area 3: Vaccination
  Recommendation
    - Offer vaccinations against hepatitis A and B, respiratory infections such as COVID-19 and influenza, and against tetanus to prevent infections and/or their complications in people who inject drugs; [...].
  Evidence and justification
    - Vaccination against infectious diseases continues to be among the most effective prevention interventions available [106]. [...] People who inject drugs are at higher risk of adverse outcomes from COVID-19 and influenza because of poor living conditions, lower access to healthcare, and impaired immunity because of co-infections and underlying medical conditions [80]. [...] Practice considerations [...]

4 COVID-19, Influenza, & RSV: 11/07/2023 Compiled by PHO Library Services
People who inject drugs should be offered the full course of vaccination against COVID-19 and seasonal influenza, as well as pneumococcal vaccination, particularly if the client is HIV positive and/or more than 50 years of age [130].

Routine or one-off vaccination services through fixed sites or mobile services serving people who inject drugs can be of particular benefit to people who inject drugs who have difficulty accessing/attending conventional healthcare services.

Offering vaccination in prison settings or residential drug rehabilitation centres can be effective in increasing vaccination uptake [32]. Outreach activities may be needed to improve vaccination uptake and completion among people who inject drugs [134,135].

**Country overview report: week 43 2023** [11-06-2023]

ECDC monitors respiratory virus activity in the EU/EEA. Data and an integrated summary of the epidemiological situation for SARS-CoV-2, influenza and RSV are available in the European Respiratory Virus Surveillance Summary.

By the end of week 43 (ending 29 October 2023), rates of respiratory illness (influenza-like illness (ILI)/acute respiratory infection (ARI)) in the community were at expected levels for this time of the year in most EU/EEA countries and were driven in part by SARS-CoV-2 transmission. Increases in case counts continued to be reported, most notably among older age groups. This has translated into sustained increases in hospital or ICU admissions and deaths in some EU/EEA countries.

Consultation rates of patients presenting to sentinel general practitioners with respiratory illness (ILI/ARI) were reported by 20 countries up to week 43. Rates remained at similar levels to those observed in the same period last year in most EU/EEA countries. Fifteen countries reported data on testing for SARS-CoV-2 in these settings, with a pooled test positivity of 20% (median of country values: 21%; IQR: 16–27%).

Recent increases in SARS-CoV-2 detections pooled at the EU/EEA level and in many individual countries appear to have peaked. However, 9 of the 17 countries reporting age-specific data observed increases among people aged 65 years and above, compared with the previous week. These trends have been observed for as long as 10 weeks in some countries. As the oldest age groups have the highest risk of severe disease, these figures highlight the importance of continuing to monitor disease and implement protective measures in older age groups.

COVID-19 admissions or numbers of inpatients in hospital or ICU have shown increasing trends over recent weeks in eight countries, although levels remained lower than at the same time last year. Death rates have also remained low, with increases compared with the previous week observed in those aged 65 years and above by 4 of 13 countries reporting age-specific death data.

Among the 16 countries reporting at least 10 results from SARS-CoV-2 sequencing or genotyping for weeks 41–42 (9 October to 22 October 2023), the estimated distribution (median and IQR of country proportions) of variants of concern (VOCs) or variants of interest (VOIs) was 69% (67–71%) for XBB.1.5+F456L, 22% (16–27%) for XBB.1.5, 4% (2–6%) for BA.2 (most of which is due to BA.2.86), and 2% (1–3%) for BA.2.75.

**Communicable disease threats report, 29 October - 4 November 2023, week 44** [11-03-2023]

**The European Respiratory Virus Surveillance Summary (ERVISS)** [10-25-2023]

**FDA: U.S. Food & Drug Administration | fda.gov**

**FDA roundup: November 3, 2023** [11-03-2023]
• Frequently asked questions on the emergency use authorization for Paxlovid for treatment of COVID-19 [11-01-2023]
• Important information about the correct dosage and administration of Moderna COVID-19 vaccine (2023-2024 formula) for individuals 6 months through 11 years of age [11-01-2023]
• Coronavirus (COVID-19) update: daily roundup [updated regularly]

UK Government | gov.uk
• UK Department of Health and Social Care
  o Government updates regulations to help deliver COVID-19 and flu jabs [10-30-2023]
• UK Health Security Agency
  o Respiratory virus unit (RVU): diagnostic services [updated 11-06-2023]
  o COVID-19 vaccination: vaccine product information [updated 11-03-2023]
  o Flu and COVID-19 surveillance report published [updated 11-03-2023]
  o National flu and COVID-19 surveillance reports: 2023 to 2024 season [updated 11-02-2023]
  o UKHSA campaign: ‘get winter strong’ with flu and COVID-19 vaccines [updated 11-01-2023]
• UK Medicines and Healthcare Products Regulatory Agency
  o Regulatory approval of Spikevax bivalent Original/Omicron booster vaccines [updated 10-20-2023]
• UK Office for Health Improvement and Disparities
  o Premature mortality during COVID-19 in adults with severe mental illness [10-19-2023]

World Health Organization | who.int
• Progress reports on technical programmes: health security, including COVID-19 and antimicrobial resistance; noncommunicable diseases and ageing; climate change, the environment and health; reaching the unreached; advancing the For the Future vision [11-07-2023]
• Influenza update N° 457 [10-30-2023]
• COVID-19 vaccine insights report - 30 October 2023 [10-30-2023]
• A checklist for respiratory pathogen pandemic preparedness planning [10-19-2023]

Other relevant government bodies / health care organizations
• BMC Public Health
  o The impact of COVID-19 on the lives of Canadians with and without non-communicable chronic diseases: results from the iCARE Study [10-26-2023]
• Canadian Centre for Occupational Health and Safety
  o COVID-19 health and safety resources [updated regularly]
• Government of Ontario
  o COVID-19 vaccines [updated 10-30-2023]
  o Free flu shot and new COVID-19 vaccines available for all Ontarians six months of age and older [10-29-2023]
- **Respiratory syncytial virus prophylaxis for high-risk infants program reference manual** [Fall 2023]
- **European Medicines Agency**
  - **Spikevax: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5** [09-14-2023]
- **US Department of Health and Human Services**
  - **Letter to COVID-19 therapeutics manufacturers, distributors, pharmacies and the health care payer community** [10-27-2023]
- **Statistics Canada**
  - **Deaths, 2021** [08-28-2023]

**Center for Infectious Disease Research Policy | cidrap.umn.edu**
- **Pilot virtual urgent care programs had marginal effect on emergency visits amid COVID** [11-07-2023]
- **Partial recall: Personal beliefs may skew pandemic memories, deepen polarization** [11-06-2023]
- **Study: 1 in 7 Americans have had long COVID** [11-03-2023]
- **Survey: Teleworking parents more stressed than those who worked onsite during pandemic** [11-03-2023]
- **People 50 and older saw cognitive declines in the first 2 years of the pandemic** [11-02-2023]
- **Americans carry ‘collective trauma’ from COVID pandemic, survey suggests** [11-02-2023]
- **US survey reveals growing distrust of vaccines, embrace of untruths** [11-01-2023]
- **Study: Paxlovid safe, effective in pregnancy** [11-01-2023]
- **Prior COVID infection lowers risk of multisystem inflammatory syndrome in kids** [11-01-2023]
- **Simulation study shows best air exchange for cruise ships** [11-01-2023]
- **COVID vaccines not linked to miscarriages** [10-31-2023]
- **Global COVID vaccination saved 2.4 million lives in first 8 months, study estimates** [10-31-2023]
- **Unapproved stem-cell therapies marketed to people with long COVID** [10-30-2023]
- **US, global COVID-19 markers show declines** [10-27-2023]

**National Collaborating Centre for Environmental Health | ncceh.ca**
- **August 2023 environmental health research scan** [08-01-2023]
- **July 2023 environmental health research scan** [07-01-2023]

**COVID-END | www.mcmasterforum.org/networks/covid-end**
- **Global spotlight 27.1: key additions for March 2023** [03-30-2023]

**ProMED | promedmail.org**
- **Latest on COVID-19** [individual posts]
- **COVID-19 update (32): updates, variants, vaccines, antivirals, scientific literature** [10-25-2023]
- **Avian influenza, human (24): Cambodia (PY, SR) H5N1, endemic clade** [10-12-2023]
Data & Real-time Tracking

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19 Note: has ceased updates as of 07-03-2023

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE)

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV)
- Genomic epidemiology of novel coronavirus (nCoV)
- Genomic analysis of nCoV spread. Situation report 2020-01-30

WHO | who.int
- WHO coronavirus (COVID-2019) dashboard

Appendices

Guidelines and Technical documents [ARCHIVED]
The guidelines were last updated 07-26-2023; news and updated guidance can be found in the New Content section above.

Appendix I: General Guidelines [ARCHIVED]
Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines
Ontario
- ON Protection from COVID-19 and other respiratory illnesses [updated 06-15-2023]

Canada (federal) and provinces and territories (other than Ontario)
- CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.'s response to COVID-19 [updated 02-11-2023]
• AB COVID-19 public health actions [no date]
• SK Living with COVID [no date]
• MB COVID-19 Novel Coronavirus [no date]
• QC Coronavirus disease (COVID-19) in Québec [updated 07-20-2023]
• NB Living with COVID-19 [no date]
• NL NL life with COVID-19 [no date]
• PEI COVID-19 [no date]
• NS Government’s response to COVID-19 [updated regularly]
• NW COVID-19 [no date]
• YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
• NT Nunavut’s Path: living with COVID-19 [no date]
• National Collaborating Centre for Indigenous Health (NCCIH): Guidance on re-opening northern, remote, isolated, and Indigenous communities [2020]

WHO
• End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: compendium of country approaches [08-02-2023]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [03-30-2023]

ECDC
• Conducting after-action reviews of the public health response to COVID-19: update [03-21-2023]

Vaccinations – General

Ontario Ministry of Health
• COVID-19 vaccine-relevant information and planning resources [updated 07-13-2023]

Canada (Federal)
• Planning guidance for immunization clinics for COVID-19 vaccines [updated 03-06-2023]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [updated 07-31-2023]
• Guidance on the use of COVID-19 vaccines in the fall of 2023 [updated 07-11-2023]
• Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series [updated 07-05-2023]
• Summary of updates in the Canadian Immunization Guide as of June 27, 2023: Updated guidance on COVID-19 vaccines in Canada [updated 06-27-2023]

Provinces and territories (other than Ontario)
• BC COVID-19 vaccine eligibility [updated 08-01-2023]
CDC
- Stay up to date with COVID-19 vaccines including boosters [updated 07-17-2023]
- COVID-19 vaccines for specific groups of people [updated 06-29-2023]

UK
- COVID-19 vaccination programme [updated 08-08-2023]
- COVID-19 vaccination: vaccine product information [07-18-2023]

ECDC
- Interim public health considerations for COVID-19 vaccination roll-out during 2023 [04-05-2023]
- Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – third update [modified 03-16-2023]
- Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [updated 03-03-2023]

Australia
- COVID-19 booster vaccine advice [updated 04-05-2023]
- Clinical recommendations for COVID-19 vaccines [updated 03-21-2023]
- ATAGI clinical guidance for COVID-19 vaccine providers [updated 02-17-2023]

Vaccinations - Adverse Effects

Canada (Federal)
- Reporting ocular adverse events following COVID-19 vaccination: Communiqué to healthcare professionals (May 30, 2022) [05-30-2022]

Provinces and territories (other than Ontario)

CDC
- Reported adverse events [updated 07-13-2023]

WHO
- Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) [03-31-2023]

UK
- Coronavirus (COVID-19) vaccines adverse reactions [updated 03-08-2023]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 01-09-2023]

Australia
- ATAGI clinical guidance on COVID-19 vaccine administration errors [updated 06-05-2023]
Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [updated 05-00-2023]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 06-06-2023]

CDC
- Coronavirus disease 2019 (COVID-19) 2023 case definition [reviewed 02-28-2023]

WHO
- WHO COVID-19 Case definition [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 12-09-2022]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [06-09-2023]

PHAC
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [modified 02-22-2023]

CDC

Miscellaneous Guidelines

PHAC
- COVID-19 and people with disabilities in Canada [updated 01-30-2023]
- Individual public health measures [updated 01-27-2023]
- Summary of evidence supporting COVID-19 public health measures [updated 01-27-2023]
WHO

- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [updated 03-30-2023]

**Data & Surveillance**

**Canada**

- COVID-19 data trends [modified 03-06-2023]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

**WHO**


**CDC**

- COVID-19 serology surveillance [03-11-2021]

**ECDC**

- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]

**Variants – Omicron**

**Canada**

- SARS-CoV-2 variants: national definitions, classifications and public health actions [08-18-2022]

**CDC**

- What is genomic surveillance? [updated 12-02-2022]

**UK**

- Investigation of SARS-CoV-2 variants [updated 03-10-2023]
- SARS-CoV-2 variants of public health interest [updated 03-10-2023]

**ECDC**

- Methods for the detection and characterisation of SARS-CoV-2 variants – second update [08-02-2022]

**Testing**

**Canada**

- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]

**Ontario Ministry of Health**

- Management of cases and contacts of COVID-19 in Ontario Version 15.2 [03-27-2023]
- COVID-19 provincial testing guidance. Version 15.3 [01-25-2023]

**Canadian provinces and territories (other than Ontario)**


**WHO**

- Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

**CDC**
• Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [updated 12-20-2022]
• Using antibody tests for COVID-19 [updated 12-16-2022]

UK
• Investigation of SARS-CoV-2 variants: technical briefings [updated 02-10-2023]
• SARS-CoV-2 variants of public health interest [updated 02-10-2023]

ECDC
• Methods for the detection and identification of SARS-CoV-2 variants- first update [08-02-2022]

Symptoms/Treatment

Canada
• COVID-19 signs, symptoms and severity of disease: a clinician guide [06-01-2022]

Ontario Ministry of Health
• Management of cases and and contacts of COVID-19 in Ontario version 15.2 [updated 03-27-2023]

BC
• Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 01-10-2023]

WHO
• WHO living guideline: drugs to prevent COVID-19 [updated 03-24-2023]
• Living guidance for clinical management of COVID-19 [11-23-2021]

CDC
• Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-09-2023]
• Clinical care information for COVID-19 [updated 01-30-2023]
• Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
• Post-COVID Conditions: Information for Healthcare Providers [updated 12-16-2022]
• Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
• Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

US NIH
• COVID-19 treatment guidelines [updated 03-06-2023]

UK
• Find help and support if you have long COVID [updated 03-29-2023]

COVID-19 Diagnosis in Children

Canada
Post-COVID-19 Condition

Canada
- Post COVID-19 condition (long COVID) [modified 03-09-2023]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2022]

WHO
- Post COVID-19 condition [12-16-2021]

CDC
- Post-COVID conditions; CDC Science [updated 03-31-2023]

UK
- Long-term effects of coronavirus (long COVID) [reviewed 03-21-2023]

Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [01-30-2023]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2022]

CDC
- Isolation and precautions for people with COVID-19 [03-21-2023]

UK
- COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [03-29-2023]

Infection Prevention and Control

PHAC / Health Canada
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [01-27-2023]
- Coronavirus disease (COVID-19): prevention and risks [01-27-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]
Ontario
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)
WHO

ECDC
- Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]

Appendix II: Guidelines for Health Sectors [ARCHIVED]
Healthcare Providers
Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19 guidance: acute care v.9 [01-11-2023]
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

UK
- COVID-19: managing healthcare staff with symptoms of a respiratory infection [03-31-2023]

ECDC
- Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]
- Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]

Congregate Living (including Long-Term Care, Prisons, and Shelters)
Ontario Ministry of Health
- COVID-19 guidance document for long-term care homes in Ontario [04-03-2023]
- COVID-19 guidance: long-term care homes and retirement homes for public health units Version 10 [03-31-2023]

PHAC

CDC
- Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities [11-29-2022]
UK
- Acute respiratory illness, including flu and COVID-19 in prisons [04-06-2023]
- Infection prevention and control in adult social care: COVID-19 supplement [04-06-2023]
- COVID-19: outbreaks in prisons, refuges and other higher-risk accommodation settings [04-04-2023]

Other
- CSC Testing of inmates in federal correctional institutions for COVID-19 [04-12-2023]

Appendix III: Guidelines for the Community [ARCHIVED]

Travel, Transport & Borders
Ontario Ministry of Health
- Travelling during COVID-19 [01-27-2023]

Canada
- Travel advice and advisories by destination [updated often]
- COVID-19: travel, testing and borders [04-03-2023]

CDC
- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines including Boosters [04-06-2023]

UK
- COVID-19: guidance for people whose immune system means they are at higher risk [03-14-2023]

Schools / Childcare
Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19: health and safety measures for child care [08-17-2022]

PHAC

CDC
- Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning [10-05-2022]
- Schools, child care, and colleges [10-25-2022]

UK
Mental Health/Substance Use Health

Ontario Ministry of Health


PHAC

- Helping people who use substances [10-01-2022]

Provinces & Territories (excluding Ontario)

- QC The roles of public health in population mental health and wellness promotion [10-03-2022]
- QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
- QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
- QC Public health ethics and COVID-19: selected resources [11-00-2021]

WHO

- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]

Back to Top

Community/Workplaces

Ontario Ministry of Health

- Protection from COVID-19 and other respiratory illnesses [04-12-2023]
- COVID-19 and workplace health and safety [03-09-2023]
- COVID-19 and your employment standards protections [06-26-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

PHAC

- Summary of evidence supporting COVID-19 public health measures [01-27-2023]
- Community based public health measures [01-27-2023]
- How businesses and employees can stay safe while operating during COVID-19 [01-27-2023]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [01-30-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]

WHO

- The generic all-hazards risk assessment and planning tool for mass gathering events [01-12-2023]

CDC

- Specific settings [12-07-2022]
UK
- Infection prevention and control in adult social care: COVID-19 supplement [04-04-2023]
- Living safely with respiratory infections, including COVID-19 [06-16-2022]

Other
- CCOHS daycares [07-14-2022]